Frederick Barrett News Today

Hallucinogens in mental health are increasingly being investigated in the drug pipeline, especially for depressive disorders and PTSD.

Drug effects have dominated the national conversation about psychedelics for medical treatment, but a new study suggests that when it comes to reducing depression with psychedelic-assisted therapy, what matters most is a strong relationship between the therapist and study participant.

Drug effects have dominated the national conversation about psychedelics for medical treatment, but a new study suggests that when it comes to reducing depressi

Drug effects have dominated the national conversation about psychedelics for medical treatment, but a new study suggests that when it comes to reducing depressi

Promising results from studies have sparked a wave of popular interest in psychedelics, amplified by writings touting their potential to reshape care for mental illness, and other care.

After half-a-century of prohibition, the United States is about to legalize psilocybin and MDMA for clinical use, to treat people suffering from post-traumatic stress disorder or terminal cancer. Scientists, patients, clandestine therapists and war veterans speak with EL PAÍS about the bright spots and shadows of this rebirth

Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.

Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.

Psychedelic startups are racing to start selling mind-expanding drugs for depression and other mental health conditions.

Psychedelic startups are racing to start selling mind-expanding drugs for depression and other mental health conditions.